CTIM-14. PELAREOREP AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) WITH STANDARD CHEMORADIOTHERAPY/ADJUVANT TEMOZOLOMIDE FOR GLIOBLASTOMA MULTIFORME (GBM) PATIENTS: REOGLIO PHASE I TRIAL RESULTS
Jessica Kendall(University of Leeds), Susan Short(Washburn University), Rachel Phillip(University of Leeds), Catherine McBain(Unknown), Anthony J. Chalmers(Beatson West of Scotland Cancer Centre), Sarah Brown(University of Leeds), Alan Melcher(University College Hospital), Adel Samson(University of Leeds)
Cited by 3
Related Papers
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial
|The Lancet|2010|640
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
|Cancer Cell|2018|591